6 Grants
2024
Molecular mechanisms of progranulin as a regulator of endothelial biology and blood pressure control
Bruder, Thiago
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 1R01HL169202-01A1), $570,263USD, 2024-09-03 -- 2029-04-30
2021
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies
BRUDER DO NASCIMENTO, THIAGO
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R00HL140139-05), $239,791USD, 2019-08-15 -- 2022-07-31
2020
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies
BRUDER DO NASCIMENTO, THIAGO
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5R00HL140139-04), $244,464USD, 2019-08-15 -- 2022-07-31
2019
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies
BRUDER DO NASCIMENTO, THIAGO
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 4R00HL140139-03), $249,000USD, 08/15/2019 -- 07/31/2022
 
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies
BRUDER DO NASCIMENTO, THIAGO
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 5K99HL140139-02), $115,506USD, 07/01/2018 -- 06/30/2020
2018
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies
BRUDER DO NASCIMENTO, THIAGO
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (ID: 1K99HL140139-01A1), $115,506USD, 07/01/2018 -- 06/30/2020